Introduction {#Sec1}
============

The prevalence of type 2 diabetes and obesity has dramatically increased in recent years, driven by changes in environment and lifestyle interacting with genetic susceptibility. Recent genome-wide association studies (GWAs) in large cohorts of patients with type 2 diabetes and obesity have revealed multiple new candidate genes for these metabolic diseases \[[@CR1]\]. Interestingly, all of the susceptibility genes for obesity strongly implicate a role for the brain, whereas most of the diabetes susceptibility genes play a role in insulin secretion and beta cell function. However, these genes explain only a small portion of the individual risk of diabetes, and it is likely that there are more candidate genes not detected by current methodology.

Inbred mouse models have been used extensively to identify genetic risk factors for obesity and type 2 diabetes \[[@CR2], [@CR3]\]. Chronic hyperglycaemia is the main feature in the diabetic state, and glucotoxicity has been implicated as playing an important role in the development of type 2 diabetes \[[@CR4]\]. Several different mechanisms have been proposed to explain the negative effects of chronic hyperglycaemia \[[@CR5]\]. For instance, it has been proposed that elevated glucose levels lead to cellular stress, which might damage insulin-producing beta cells \[[@CR6]\]. Nevertheless, the significance of data from transcriptional studies of islet cells is limited, since the arduous conventional collagenase digestion protocol for procuring pancreatic islets is known to alter gene expression patterns as observed in collagenase-isolated primary adipose cells \[[@CR7]--[@CR9]\]. In fact, collagenase digestion has been reported to induce a marked increase in expression of proinflammatory genes and of genes involved in hypoxia-induced stress and apoptosis, respectively, i.e. the very same pathways that have been implicated in the pathophysiology of glucose-induced beta cell death \[[@CR8]\]. We recently introduced the New Zealand obese mouse (NZO) mouse strain as a suitable disease model for studying the role of dietary carbohydrates in the pathophysiology of high fat-diet induced diabetes \[[@CR10]\]. In this model, a carbohydrate-containing high-fat diet (HF) is highly diabetogenic whereas a carbohydrate-free high-fat diet (CHF) protects from diabetes \[[@CR10]\]. In the present study we isolated authentic pancreatic islets with laser capture microdissection (LCM) and performed genome-wide expression analyses with samples from HF- and CHF-treated animals. Our results support the concept that glucose-induced oxidative stress in islets is relevant for disease progression.

Methods {#Sec2}
=======

**Experimental animals** Up to six male New Zealand (NZL)/LtJ mice (The Jackson Laboratory, Bar Harbor, MA, USA) were housed per cage (macrolon type III) at a temperature of 22°C with a 12 h light--dark cycle (lights on at 06:00 hours). The animals were kept in accordance with the NIH guidelines for the care and use of laboratory animals and all experiments were approved by the Ethics Committee of the State Ministry of Agriculture, Nutrition and Forestry (State of Brandenburg, Germany). After weaning at 3 weeks, the animals received either a HF diet (10105721; Altromin, Lage, Germany) (14.6% \[wt/wt\] fat, 46.8% carbohydrates, 17.1% protein) or a CHF diet (10105789; Altromin) (30.2% \[wt/wt\] fat, 0% carbohydrates, 26.4% protein) diet. Throughout the study the animals had free access to food and water.

**Analysis of body composition** Body composition and body weight were measured weekly. Body composition was measured by nuclear magnetic resonance (Echo MRI Whole Body Composition Analyzer; Echo Medical Systems, Houston, TX, USA).

**Blood glucose and plasma insulin** Blood glucose was measured weekly under non-fasting conditions in blood samples collected from the tail vein with a blood glucose meter (Ascensia Elite; Bayer Health Care, Leverkusen, Germany). Insulin levels were determined by ELISA (insulin mouse ultra-sensitive ELISA; DRG Instruments, Marburg, Germany).

**Glucose tolerance tests** At 8 weeks, animals were fasted for 16 h before the experiment. Each animal received a single i.p. injection of glucose (20% solution, 2.0 g/kg body weight). Samples for determination of blood glucose and plasma insulin concentration were collected at 0, 7.5, 15, 30, 60, 120 and 240 min from the tail tip. Mice were kept in their accustomed cage and had free access to water.

**Quantitative real-time PCR** Isolated islet RNA (20--50 ng) was amplified with a whole transcriptome amplification kit (TransPlex; Sigma-Aldrich, Seelze, Germany). The amplified cDNA was purified with a PCR clean-up kit (GenElute; Sigma-Aldrich). Quantitative real-time PCR was performed with the 7300 Real-Time PCR System (Applied Biosystems, Darmstadt, Germany). The PCR mix (25 µl) was composed of TaqMan universal PCR Master Mix (10 µl; Applied Biosystems), TaqMan-Probe (1 µl; Applied Biosystems) and 10 ng of cDNA per reaction. Relative gene expression was calculated by the ∆∆*C*~t~ method with *Actb* as control gene \[[@CR11]\]. Expression differences between groups were tested with Mann--Whitney--Wilcoxon test. *p* values below 0.05 were considered statistically significant.

**Laser capture microdissection and total RNA isolation** Pancreatic sections were prepared at 14 µm thickness using a cryostat (Leica, Wetzlar, Germany) and mounted on RNase-free membrane-coated slides (P.A.L.M., Wolfratshausen, Germany). Immediately before microdissection, sections were fixed in ethanol and then rehydrated in 75% and 50% ethanol (vol./vol.) for 30 s each. Sections were stained with filtered cresyl violet acetate (Ambion) for 1 min to allow for identification of islets. Next, sections were dehydrated with a graded alcohol series (50%, 75% and 100 % and 100% (vol./vol.), 30 s each). Finally, the slides were placed in HistoClear (National Diagnostics, Atlanta, GA, USA) for 2 min and left to air-dry under the hood. Out of ten evenly spaced Nissl-stained sections, 500 islets were dissected using a LCM system (P.A.L.M.). Samples were stored in 20 µl of RNAlater (Ambion). Total RNA was isolated from the LCM samples using an RNA extraction kit (RNAqueous Micro; Ambion) following the manufacturer's instructions. RNA concentrations were determined using a spectrophotometer (NanoDrop ND-1000; Thermo Scientific, Wilmington, DE, USA). Quality of the RNA was determined with BioAnalyzer 2100 (Agilent, Böblingen, Germany). The RNA integrity value was used as an indicator of RNA quality. Only samples with a RNA integrity value over 4.5 were used for further analysis. Analysis of the coefficients of variation of biological replicate hybridisations confirmed homogenous RNA preparations of sufficient quality for microarray experiments (Electronic supplementary material \[ESM\] Fig. [1](#MOESM5){ref-type="supplementary-material"}).

**Amplification and labelling of LCM-isolated islet RNA** For labelling of the isolated islet RNA we used an RNA amplification system (WT-Ovation Pico; NuGEN, San Carlos, CA, USA) with 100 ng RNA per reaction to produce labelled cDNA.

**Hybridisation of Affymetrix microarrays** For genome-wide transcriptome analysis, we used the Affymetrix Mouse Genome 430 2.0 Array platform ([www.affymetrix.com/products_services/arrays/specific/mouse430_2.affx](http://www.affymetrix.com/products_services/arrays/specific/mouse430_2.affx); version 09.01.2008). LCM-isolated islets from each mouse were processed separately. Labelled cDNA (5 µg) was hybridised on to each array. We analysed NZL samples from isolated islets and total pancreas with respect to two nutritional conditions induced by the HF and CHF diets.

**Data processing** The pre-processing and analysis of the microarray data was performed with the R/BioConductor software platform \[[@CR12]\]. Arrays for each individual case--control study were normalised using the GC RMA method \[[@CR13]\]. Affymetrix gene chip annotations were adapted from latest genome annotations in version 9, based on Ensembl 42, and resulting in 15,758 Ensembl genes \[[@CR14]\]. Additional annotation for the Ensembl genes is based on Ensembl 46. Presence tags were calculated following Affymetrix procedures. For quality control, we analysed the coefficient of variation of the raw probe fluorescence intensities for all biological replicates in the hybridisation experiments (ESM Fig. [1](#MOESM5){ref-type="supplementary-material"}). Differential expression was judged by three criteria: (1) the gene is expressed in at least one of the samples, treatment or control. at *p* ≤ 0.05; (2) the fold-change is \>4/3 or \<3/4; and (3) the Welsh test *p* value is *p* \< 0.05.

**Identification of disease-related networks using enrichment analyses** Disease-related networks were investigated with two different types of functional information: (1) biological pathways \[[@CR15]\] as provided by the KEGG database ([www.genome.jp/kegg/](http://www.genome.jp/kegg/); version 09.01.2008); and (2) functional categories using Gene Ontology annotations (Ensembl 41) \[[@CR16]\]. These functional information terms define groups of associated genes. Using enrichment analyses with hypergeometric distribution \[[@CR17]\], we were able to assign each annotation term a *p* value that reflects enriched occurrence of differentially expressed genes. In case of Gene Ontology terms, we included only genes with evidence codes inferred from direct assay (IDA), mutant phenotype (IMP), traceable author statement (TAS) or by curator (IC) in order to ensure a high confidence level.

**Immunohistochemistry** Pancreatic tissue was fixed in 4.5% (w/v) formaldehyde and embedded in paraffin according to standard procedures. Sections (2 µm) were stained with haematoxylin. Endogenous peroxidase activity in the sectioned tissues was blocked with 3% (*v*/*v*) H~2~O~2~ and non-specific binding sites were blocked with non-immune goat serum. Subsequently, rabbit polyclonal antibody to carbohydrate-responsive element binding protein (ChREBP; 1:500; GeneTex, Irvine, CA, USA) was applied and stained with biotin-conjugated donkey anti-rabbit IgG and streptavidin--biotin--horseradish peroxidase complex (Dianova, Hamburg, Germany) and diaminobenzidine (Dako Diagnostika, Hamburg, Germany) as substrate according to the manufacturer's instructions. A ChREBP antibody/peptide complex (aa 800-852; NP_116569; GeneTex) served as control for non-specific binding.

Results {#Sec3}
=======

**A carbohydrate-free high-fat diet protects from hyperglycaemia and beta cell failure** Male NZL mice were raised on two different diets, namely HF (35% calories from fat) and CHF (72% calories from fat). As illustrated in Fig. [1a](#Fig1){ref-type="fig"}, the body weight of the animals was similar on both diets, reaching approximately 55 g in week 17. NZL mice also developed a similar degree of obesity on both diets, with fat depots reaching 36% of total body weight (∼18 g total body fat; Fig. [1b](#Fig1){ref-type="fig"}). However, whereas most animals on the HF developed severe hyperglycaemia beginning at week 8, with blood glucose levels progressively increasing, animals on the CHF maintained normal glycaemia until the end of the dietary intervention (Fig. [1c](#Fig1){ref-type="fig"}, ESM Fig. [2](#MOESM6){ref-type="supplementary-material"}). At week 8, animals from both diet groups displayed severe glucose intolerance and, as described earlier \[[@CR18]\], a markedly blunted early-phase secretion of insulin in response to a glucose bolus (Fig. [1e](#Fig1){ref-type="fig"}). At week 17, the prevalence of diabetes (blood glucose levels \>13.88 mmol/l) in HF mice was 63%. In contrast, no incidence of diabetes was observed in the CHF group (ESM Fig. [2](#MOESM6){ref-type="supplementary-material"}). Fig. 1A CHF diet protects from hyperglycaemia and diabetes. **a** Body weight of 17-week-old male NZL mice fed either HF or CHF. **b** Body fat content. **c** Blood glucose levels at week 17. **d** Plasma insulin levels at week 22. Values were derived from 14 to 16 animals per group. **e** Intraperitoneal glucose tolerance test at week 8, five animals per group. Values are mean ± SE. White circles, CHF plasma glucose; black circles, HF plasma glucose; white triangles, CHF plasma insulin; black triangles, HF plasma insulin

**Enrichment of transcripts in islets** To assess the effectiveness of our islet isolation procedure, we performed quantitative real-time PCR with cDNA derived from laser-captured islets and cDNA from whole pancreas preparations. As shown in Fig. [2](#Fig2){ref-type="fig"}, the cDNAs for the islet-specific glucose transporter *Slc2a2*, *Foxo1* and *Gcg* were enriched in islet preparations. To obtain a profile of global transcript abundance in islets, we compared whole-genome expression data from islets of 8-week-old CHF-fed mice with data obtained by hybridisation of RNA from total pancreas of matched animals. As expected, the list of the most abundant transcripts in islets included insulin, glucagon, islet amyloid polypeptide, carboxypeptidase E and other well established genes expressed in alpha and beta cells (ESM Table [1](#MOESM1){ref-type="supplementary-material"}). Transcripts required for protein synthesis, protein secretion and oxidative phosphorylation were also highly abundant in the isolated islets. In contrast, the highest expression levels in total pancreas were observed for hydrolytic enzymes, including pancreatic proteases, lipases and nucleases (data not shown). To identify islet-specific transcripts, we calculated a simple enrichment score by dividing the median-normalised fluorescence intensities from islet and pancreas samples for each transcript. Of the ∼10,000 genes expressed, we identified 238 transcripts that were highly enriched (≥ tenfold) in islets vs total pancreas (ESM Table [2](#MOESM2){ref-type="supplementary-material"}). The list of enriched transcripts includes numerous well-known genes thought to play critical roles in islet functions such as insulin production (e.g. *Cpe*, *Pcsk1*, *Pcsk2*) and secretion (e.g. *Abcc8*, *Ucn3*, *Glp1r*, *Sst*, *Slc2a2*, *Snap25*), and cell growth and differentiation (e.g. *Pax6*, *Neurod1*, *Cdkn1b*), as well as genes associated with type 2 diabetes in recent human genome-wide scans (*Wfs1*, *Slc30a8*; ESM Table [2](#MOESM2){ref-type="supplementary-material"}). Conversely, ∼400 transcripts were highly enriched (≥ tenfold) in total pancreas vs islets, including the well-known pancreatic hydrolases, *Cckar* and members of the Reg gene family, all three of which have been implicated in islet cell regeneration (data not shown). However, expression of transcripts derived from exocrine pancreatic cells was greatly reduced in islet preparations (ESM Table [3](#MOESM3){ref-type="supplementary-material"}). Yet, for a number of genes with robust islet-selective expression, the biological function is unknown. Fig. 2Enrichment of selected islet genes in LCM samples. mRNA expression genes was determined by quantitative TaqMan RT-PCR for each gene and for *Actb* from LCM islets (white bars) and total pancreas (black bars) of 8-week-old mice. Expression levels are presented as change in *C*~t~ or the cycle number of each gene subtracted from the cycle number of beta-actin (*C*~t~ value 20.15) for the same cDNA sample. Lower numbers thus correspond to higher expression. Data are means ± SE from five CHF-fed NZL mice. \**p* ≤ 0.05

**Comparison with GWAs for type 2 diabetes** Over recent years, GWAs have revealed numerous genetic loci, some of which have been implicated in the pathogenesis of diabetes, insulin secretion and beta cell survival. To determine how successful our approach was in identifying plausible novel candidates, we compared differentially expressed genes from our mouse model for diet-induced diabetes with previously reported single nucleotide polymorphisms (SNPs) associated with type 2 diabetes in humans. We used data from two publicly available genome-wide scans, the Diabetes Genetics Initiative (DGI) study \[[@CR19]\] and the Wellcome Trust Case Control Consortium (WTCCC) GWA for diabetes \[[@CR20]\]. We compiled a list of 837 SNPs that map to 439 known human genes and are nominally associated with diabetes (*p* \< 0.05) in both scans. Of the 430 mouse orthologue genes, 39 mouse genes were differentially expressed ≥1.5-fold) in our study (Table [1](#Tab1){ref-type="table"}, ESM Fig. [3](#MOESM7){ref-type="supplementary-material"}). Interestingly, the list includes two genes from genetic loci found to be associated with diabetes in recent GWAs, *IGF2BP2* \[[@CR20], [@CR21]\] and *TSPAN8-LGR5* \[[@CR22]\], as well as *CACNA1D*, which is required for pancreatic beta cell generation in mice \[[@CR23]\]. We selected nine differentially expressed genes and performed quantitative real-time PCR with RNA from LCM-isolated islets and with RNA from total pancreas. As illustrated in ESM Fig. [4](#MOESM8){ref-type="supplementary-material"}, we were able to validate all five selected genes that were downregulated by the HF, including *Dach1*, *Clip2*, *Cacna1d*, *Igf2bp2* and *Chd2*. In contrast, we were not able to confirm HF-induced upregulation of *Ldlrad3*, *Sil1*, *Plekha1* and *Pdia3* by quantitative real-time PCR. Table 1Differentially expressed mouse islet genes with significant association with human type 2 diabetes in two genome-wide scansSymbolRatioSNPsDGI T2DWTCCC T2DHF/CHF^a^Islets/pancreas^b^ID^c^OR^d^*p* value^e^*p* value^f^*Abcc4*1.7891.59rs17510521.1790.0260.018^g^*Arhgap24*1.5161.170rs126404110.8550.0270.025^g^rs125065960.8460.0180.024^g^rs126442600.8440.0190.038^g^rs46937160.8490.0230.026^g^rs13841350.8420.0160.027^g^rs13841340.8400.0170.026^g^rs98849320.8450.0180.025^g^rs100004720.8450.0180.026^g^rs173893000.8480.0200.024^g^*Cacna1d*^h^0.5222.70rs124874520.7960.0180.024^g^*Camkk2*0.5152.96rs98051300.8410.0040.044^g^*Car8*1.7711.13rs102164400.8330.0260.001^g^*Chd2*^h^0.53221.00rs14067121.3790.0390.023^g^*Clip2*^h^0.4357.91rs25289941.1180.0200.021^g^rs5120231.0980.0290.042^g^*Cobll1*2.3480.19rs67178580.8920.0270.026^g^*Ctnnd2*1.8779.39rs68736711.1380.0250.034^i^*Esyt2*1.6020.47rs38164651.1980.0370.009^i^rs68734901.1370.0190.030^i^*Dach1*^h^0.3528.78rs79912931.4690.0190.010^i^*Elf1*1.8550.24rs95254381.1430.0340.018^i^rs77991.1430.0280.005^i^rs95326911.1480.0240.007^i^*Fam45a*1.5710.60rs47522500.8560.0430.005^g^rs111987830.8370.0150.005^g^*Gnaq*1.5410.93rs65606130.7770.0340.007^g^rs47456640.8390.0240.040^g^*H2-Ea*1.8060.41rs71940.8720.0410.045^g^*Hnrnpc*1.5820.87rs170925230.9360.0330.001^i^rs49824370.9140.0210.010^i^rs74950.9290.0280.005^i^rs80098940.9410.0460.006^i^rs71412300.9380.0390.004^i^rs71476550.9350.0360.007^i^*Igf2bp2*^h^0.4935.74rs44029601.1100.0340.002^g^rs76510901.1030.0390.002^g^*Igf2r*1.9041.24rs109456450.7800.0070.039^i^rs37981970.8690.0280.032^i^rs92951190.8360.0400.012^i^*Inpp5d*0.5882.51rs101768950.75830.0430.025^g^rs101894880.7350.0180.035^g^rs102002710.70840.0220.045^g^*Klhl21*1.6881.22rs15560361.1220.0310.008^i^*Ldlrad3*5.2743.56rs123617380.8690.0200.023^g^*Lyar*1.520.158rs29800891.2170.0160.05^g^*Mphosph6*1.9410.96rs18628201.2010.0090.004^g^*Nampt*1.5840.48rs47301550.9090.0430.012^g^*Pdia3*3.3840.50rs80403360.8520.0120.045^g^*Pdlim5*0.5614.80rs68300740.8040.0470.003^g^rs68120980.7900.0410.015^g^*Phactr1*0.52533.9rs176175840.7700.0270.048^g^rs92964860.7940.0090.043^g^rs92964880.7990.0110.032^g^rs93493500.8020.0120.023^g^rs93575030.8370.0330.028^g^rs93814390.8040.0130.035^g^*Ppfia3*0.64.41rs37646251.1320.0230.003^g^*Pkib*2.2891.52rs170846801.0850.0250.614^g^*Plekha1*2.4240.51rs171035411.3030.0230.028^g^*Qpct*3.930.52rs22559911.3680.0290.01805^g,i^*Sil1*1.9510.57rs15606560.8710.0220.042^i^*Stxbp6*1.8250.19rs172577731.3520.0060.024^i^*Tacr3*2.1381.27rs13844010.8280.0110.015^g^rs50056340.8350.0110.011^g^rs76636640.8210.0090.010^g^*Tmem135*1.7660.72rs108985891.4280.0180.044^g^rs108985901.4490.0130.009^g^*Tspan8*3.9931.35rs105066250.8600.0190.00007^g^rs105066261.1460.0150.00002^g^rs111786481.1580.0140.00005^g^rs22705841.1460.0120.00002^g^*Ube2z*1.7590.94rs155630.9030.0310.028^i^rs465220.9060.0400.025^i^rs19949700.9070.0400.033^i^rs47939920.9040.0430.029^i^*Xkr6*0.5373.11rs70163851.1150.0330.019^g^Expression of genes was determined with mRNA from LCM islets and from total pancreas of 8-week-old mice^a^Only genes with a significant fold-change (*p* ≤ 0.05) were included^b^Ratio of median-normalised fluorescence intensities from islet and pancreas samples for each transcript^c^Only SNPs with *p* ≤ 0.05 in both GWAs \[[@CR19], [@CR20]\] were included^d,e^Odds ratios and *p* values for association with type 2 diabetes in DGI study^f^As above (^d,e^) in WTCCC Study^g^Additive model; ^h^differential expression validated by quantitative real-time; ^i^general model

**Diet-dependent differentially expressed genes** We identified 3,027 differentially expressed genes in islets of HF- and CHF-fed NZL mice. Of those, 2,109 genes showed at least 1.5-fold changes in gene expression, with 1,496 genes upregulated and expression of 613 genes decreased in response to the HF. We categorised the top 50 differentially expressed genes according to their known or putative biological function and grouped these genes into the following categories of genes involved in: (1) growth and development; (2) protein processing and secretion; (3) metabolism; and (4) signalling (Table [2](#Tab2){ref-type="table"}). In the islets, HF induced gene expression changes associated with increased cell cycle progression, proliferation and differentiation, such as *Cdkn1b*, *Tmem27* and *Pax6* (Table [2](#Tab2){ref-type="table"}). Also, several genes involved in insulin production and secretion were differentially regulated by the HF, such as *Pcsk1* and *Pcsk2* (Table [2](#Tab2){ref-type="table"}). Moreover, known regulators of the cellular redox state such as *Txnip*, *Cat*, *Gpx1* and *Prdx1* to *Prdx5* were increased up to fourfold in the islets of HF-fed animals (Table [2](#Tab2){ref-type="table"}). From each of the four functional categories, growth and development, protein processing and secretion, metabolism, and signalling, we selected one to two differentially expressed genes and performed quantitative real-time PCR with RNA from LCM-isolated islets and RNA from total pancreas. As illustrated in Fig. [3](#Fig3){ref-type="fig"}, diet-induced changes in expression levels for *Cacna1d*, *Cck*, *Mlxipl*, *Txnip* and *Tmem27* were validated by quantitative real-time PCR in LCM islets. However, the mRNA levels for *Cacna1d*, *Mlxipl*, *Txnip* and *Tmem27* were not or only slightly changed by the diet in RNA from total pancreas, indicating that differential expression was restricted to islet cells (data not shown). Moreover, mRNA for *Cck* (HF-*C*~t~ value in islets ∼25) was not detected in total pancreas. Table 2Diet-dependent differentially expressed genes in isletsSymbol per categoryDescriptionRatio (HF/CHF)^a^Growth and development *Pax6*Paired box gene 60.51 *Cdkn1b*Cyclin-dependent kinase inhibitor 1B0.40 *Pura*Purine rich element binding protein A0.37 *Dach1*Dachshund 1 (*Drosophila*)0.35Metabolism *Gmds*GDP-mannose 4, 6-dehydratase5.02 *Ndufa1*NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 14.80 *Sqle*Squalene epoxidase4.64 *Atp5b*ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit4.40 *Prps1*Phosphoribosyl pyrophosphate synthetase 14.23 *Suclg1*Succinate-CoA ligase, GDP-forming, alpha subunit4.14 *Pon3*Paraoxonase 34.13 *Scd1*Stearoyl-Coenzyme A desaturase 12.80 *Pfkfb2*6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 20.41 *Cyp4a10*Cytochrome P450, family 4, subfamily *a*, polypeptide 100.35 *Chkb*Choline kinase beta0.34 *Eno3*Enolase 3, beta muscle0.34 *Mlxipl*MLX interacting protein-like0.29 *Gmds*GDP-mannose 4, 6-dehydratase0.20Protein processing and secretion *Rps27l*Ribosomal protein S27-like5.05 *Psmb7*Proteasome (prosome, macropain) subunit, beta type 74.85 *Vamp8*Vesicle-associated membrane protein 83.15 *Pcsk1*Proprotein convertase subtilisin/kexin type 12.73 *Pcsk2*Proprotein convertase subtilisin/kexin type 21.92 *Vti1b*Vesicle transport through interaction with t-SNAREs 1B homologue1.88 *Vamp5*Vesicle-associated membrane protein 50.40 *Sec24a*SEC24 related gene family, member A (*S. cerevisiae*)0.38Signalling *Cck*Cholecystokinin9.25 *Rheb*RAS-homologue enriched in brain4.82 *Dusp6*Dual specificity phosphatase 64.26 *Cacna1d*Calcium channel, voltage-dependent, L type, alpha 1D subunit0.52 *Rps6kb2*Ribosomal protein S6 kinase, polypeptide 20.40 *Nlgn1*Neuroligin 10.34 *Vipr1*Vasoactive intestinal peptide receptor 10.33 *P2ry6*Pyrimidinergic receptor P2Y, G-protein coupled, 60.28Regulation of redox status *Txnip*Thioredoxin interacting protein4.14 *Prdx4*Peroxiredoxin 43.10 *Prdx5*Peroxiredoxin 42.74 *Cat*Catalase1.95 *Gpx1*Glutathione peroxidase 12.26Other *Ctss*Cathepsin S12.98 *Cldn11*Claudin 1111.32 *Spp1*Secreted phosphoprotein 14.55 *Alg5*Asparagine-linked glycosylation 5 homolog4.54 *Tmem27*Transmembrane protein 271.94The top 44 differentially expressed genes (HF vs CHF) were categorised according to their known or putative biological function^a^Mean of five to six Affymetrix chips per condition; only genes with a significant fold-change were included (*p* ≤ 0.05)Fig. 3Validation of differential expression in islets by quantitative real-time PCR. TaqMan quantitative PCR validation of genes differentially regulated between CHF (white bars) and HF (black bars). The change in expression is shown for selected genes involved in islet growth and development, protein processing and secretion, metabolism, and signalling. Values are normalised to *Actb.* Data are mean ± SE of five separate mice per group. \**p* ≤ 0.05Interestingly, islet mRNA for *Chrebp* (also known as *Mlxipl*), a transcription factor that has emerged as a key determinant of lipid synthesis and a major mediator of hepatic conversion of glucose into fat \[[@CR24]\], was also significantly decreased in response to the diabetogenic HF (Table [2](#Tab2){ref-type="table"}), a finding validated by quantitative real-time PCR (Fig. [3](#Fig3){ref-type="fig"}). Immunohistochemical staining of pancreatic sections from NZL and C57BL/6J mice confirmed presence of ChREBP protein in islet cells (Fig. [4a--d](#Fig4){ref-type="fig"}), although we were unable to quantify its nuclear localisation. According to quantitative real-time PCR analysis, expression of *Chrebp* mRNA was comparable in liver and islet tissue. However, only in the liver of the animals, did the HF result in substantial upregulation of *Pklr*, *Scd1* and malic enzyme, whereas no significant changes in gene expression levels were observed in the corresponding islets of the animals (Fig. [4e](#Fig4){ref-type="fig"}). Fig. 4Islet levels of ChREBP and regulation of lipogenic target genes. Immunohistochemical detection of ChREBP in pancreatic sections from male NZL mice. HF (**a**) and CHF fed (**b**) animals at week 8, with (**c**, **d**) respective controls with blocking peptide. **e** TaqMan quantitative PCR validation of ChREBP target genes in islets. Values are normalised to *Actb*. Data are mean ± SE of five separate mice per group; \**p* ≤ 0.05. White bars, CHF; black bars, HF; Grey bars, CHF liver; hatched bars, HF liver. *Srebp-1* (also known as *Srebf1*)

**Pathway analysis** The set of differentially expressed genes was used to perform pathway analysis as described. Gene set enrichment of the most significant KEGG pathways revealed differential expression of genes involved in mitochondrial oxidative phosphorylation, proteasome, ribosome, pyruvate metabolism, terpenoid biosynthesis, N-glycan biosynthesis, bisphenol A degradation and reductive carboxylate cycle (Table [3](#Tab3){ref-type="table"}, ESM Table [4](#MOESM8){ref-type="supplementary-material"}). Oxidative phosphorylation was the most significantly over-represented pathway (2.31E−12) whose expression was differentially regulated between HF and CHF. About half of the genes annotated for oxidative phosphorylation (OXPHOS), proteasome and ribosome were differentially expressed in islets in response to the dietary regiment. In fact, the majority of these genes annotated for these three pathways were upregulated in response to HF (Table [3](#Tab3){ref-type="table"}). To confirm this observation, we performed quantitative real-time PCR on six OXPHOS genes that are derived from complex I (*Ndufa8*, *Ndufb9* and *Ndufc2*) and on one from each of complexes II, III and IV (*Sdhd*, *Uqcrc2* and *Cox5a*, respectively). With the exception of *Uqcrc1* from complex III, each transcript was upregulated in response to HF, with significant changes for *Ndufa8*, *Ndufb9 and Ndufc2* (Fig. [5](#Fig5){ref-type="fig"}). Table 3Gene set enrichment analysis of 3,027 genes differentially regulated by HF and/or CHF diet in isletsKEGG pathway description*p* valueSet^a^Sig.Set^b^Sig.Set, upregulated^b^Sig.Set, downregulated^b^Oxidative phosphorylation2.31 × 10^−12^9649463Proteasome1.41 × 10^−7^2517170Ribosome0.00297211091Pyruvate metabolism0.006393714122Terpenoid biosynthesis0.007083321*N*-Glycan biosynthesis0.008363814131Bisphenol A degradation0.008517862Reductive carboxylate cycle0.009511660Only pathways with significant changes (*p* ≤ 0.01) were included^a^Number of genes in KEGG pathway; ^b^differentially expressed genesFig. 5TaqMan quantitative PCR validation of OXPHOS genes in islets. The changes in expression of selected OXPHOS genes are shown. Values are normalised to *Actb*. Data are mean ± SE of five separate mice per group; \**p* ≤ 0.05. White bars, CHF; black bars, HF
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To identify potentially relevant candidate genes involved in type 2 diabetes, we used a model of beta cell failure, NZL mice, fed either a HF or a CHF diet. To gain insights into the pathophysiology of diet-induced beta cell failure and the metabolic pathways mediating downstream effects of the HF, we isolated pancreatic islets with LCM and performed genome-wide expression analyses. Consistent with previous findings \[[@CR10], [@CR25]\], our data clearly demonstrate the critical role of dietary carbohydrates in the pathophysiology of high fat-diet induced diabetes. In the obese NZL mice as well as the related NZO strain, a CHF protects from hyperglycaemia and beta cell failure, whereas a carbohydrate-containing HF diet is highly diabetogenic \[[@CR10]\]. Since both diets induce a similar degree of adiposity and glucose intolerance, the beta cell toxicity is likely to be due to elevated glucose concentrations.

As expected, numerous genes known to be highly expressed in islets, such as insulin, glucagon and islet amyloid polypeptide, were also highly abundant in the LCM samples. In fact, about 2.5% of all transcripts expressed were highly enriched in islets cells compared with total pancreas. Moreover, many of those transcripts have not been linked to islet cell function previously and may therefore represent novel candidate genes with relevant functions in islet cell biology. Most importantly, however, islet RNA isolated with LCM is likely to reflect the transcriptome of these cells more accurately, compared with the conventional collagenase-digestion method used for islet isolation \[[@CR7], [@CR8]\]. In fact, the latter procedure has been reported to induce marked increases in gene expression of proinflammatory genes and of genes involved in hypoxia-induced stress and apoptosis, thereby severely impairing interpretation of expression data derived from metabolically stressed islet cells \[[@CR7], [@CR8]\]. Thus, LCM represents an ideal tool to obtain native islet samples without inducing the stress-response of islet isolation.

Recent GWAs have revealed numerous genetic loci associated with type 2 diabetes in humans \[[@CR1]\]. So far, there has been a lack of functional data about the involvement of these variants in the pathogenesis of diabetes. However, most of these genes were found to be highly expressed in islets \[[@CR1]\]. We identified 39 genes that are highly expressed in the pancreas and were differentially expressed in our mouse model of diet-induced diabetes and nominally associated with diabetes in two independent GWAs, the DGI study and the WTCCC scan for diabetes, respectively \[[@CR19], [@CR20]\], thus validating our approach (Table [1](#Tab1){ref-type="table"}). Among these genes is *CACNA1D*, the voltage-dependent calcium channel, which has been shown to be required for pancreatic beta cell generation in mice \[[@CR23]\]. Interestingly, the list also includes two loci that have been found to be associated with type 2 diabetes in recent GWAs, *IGF2BP2* \[[@CR19], [@CR21]\] and *TSPAN8-LGR5* \[[@CR22]\]. With regard to the latter region, the most significant association with type 2 diabetes in a meta-analysis of three GWA scans was observed for rs7961581 (*p* = 1.1 × 10^−9^), which maps in the intergenic region between *TSPAN8* and *LGR5* \[[@CR22]\]. In mouse islet cells, the diabetogenic HF increased expression of *Tspan8* approximately fourfold, whereas *Lgr5* expression was not changed (Table [3](#Tab3){ref-type="table"}, data not shown). Thus, our data provide evidence that *TSPAN8* is more likely to be functionally related to the development of type 2 diabetes than *LGR5.* It should be mentioned, however, that our approach has limitations, since we only took into account the two publicly available genome-wide scans on type 2 diabetes susceptibility genes. Moreover, the overlap of differentially expressed genes in islets and genes found in the two GWAs amounts roughly to the number expected by chance. However, this number is likely to be underestimated, because not all genes were tested for association with type 2 diabetes in the merged scans.

Exposure to HF resulted in a substantial number of differentially expressed genes in the islets, reflecting prominent changes of the expression pattern in response to the diet. In fact, the majority of these genes (\>80%) were upregulated in HF islets. We have previously shown that in the prediabetic state, HF induces massive hyperglycaemia in the related NZO strain and compensatory hyperplasia of pancreatic islets \[[@CR10], [@CR26], [@CR27]\]. Consistent with these data, HF induced gene expression changes associated with increased islet growth and insulin production, such as increased expression of *Tmem27*, the proapoptotic thioredoxin-interacting protein *Txnip*, *Cck* and *Pcsk2*, and downregulation of *Cacna1d* \[[@CR23], [@CR28]--[@CR30]\].

Most strikingly, genes for OXPHOS were substantially upregulated by the HF, demonstrating enhanced oxidative metabolism in islets of animals receiving HF or high-carbohydrate diet. Moreover, the majority of enzymes for pyruvate metabolism and TCA cycle were significantly upregulated by the HF, suggesting an increased flux of fatty acid-derived acyl-CoA towards mitochondrial oxidation in the presence of dietary carbohydrates. Thus, increased availability of carbohydrates stimulates oxidative metabolism in islets, presumably by providing sufficient TCA intermediates in the mitochondrial matrix (anaplerosis).

Alterations in expression of OXPHOS genes has been regarded as a key change in the insulin-resistant state in human patients and animal models of type 2 diabetes \[[@CR31]--[@CR33]\]. Since OXPHOS is a major source of reactive oxygen species (ROS) production, increased mitochondrial oxygen flux leads to increased formation of ROS \[[@CR34]--[@CR37]\]. ROS include highly reactive moieties, such as superoxide anions, hydrogen peroxide and hydroxyl radicals, which have been implicated in the pathogenesis of diabetes \[[@CR38], [@CR39]\]. Consistent with elevated ROS production in HF islets, the gene expression of regulators of the cellular redox state, including catalase, glutathione peroxidase 1, peroxiredoxins and thioredoxin interacting protein, was increased, strongly implicating ROS in the early state of beta cell failure. Proteomic analysis of isolated islets may be used to further investigate the diet-induced alterations in OXPHOS gene expression and protein modifications in response to increased oxidative stress.

Among the most differentially expressed genes in response to the dietary intervention were the transcription factor *Chrebp* and the peptide hormone *Cck*. Interestingly, cholecystokinin mRNA, which was upregulated about tenfold by the HF, appears to be highly enriched in LCM islets. Recent evidence suggests that cholecystokinin acts as a proliferative signal on beta cells \[[@CR28]\], implicating it in the compensatory hyperplasia of islet cells in the prediabetic state. ChREBP has been described as a transcriptional sensor for glucose in the liver, which becomes activated upon glucose stimulation and triggers production of lipogenic enzymes for conversion of glucose into fat \[[@CR24]\]. We confirmed ChREBP protein production in islets by immunohistochemistry (Fig. [4a--d](#Fig4){ref-type="fig"}). Moreover, *Chrebp* mRNA levels in islets and liver were comparable (Fig. [4e](#Fig4){ref-type="fig"}). Consistent with previous reports \[[@CR24]\], HF-induced hyperglycaemia resulted in activation of ChREBP in the liver and subsequent induction of lipogenic enzymes, including acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1 and liver-type pyruvate kinase (Fig. [4e](#Fig4){ref-type="fig"} and data not shown). Interestingly, in islets, ChREBP was considerably decreased in response to the diabetogenic HF, whereas transcription of ChREBP target genes was not affected, clearly indicating that in islets ChREBP controls different target genes than in the liver. In fact, a recent report demonstrated that ChREBP mediates glucose-induced expression of proapoptotic *Txnip* and induces H4 acetylation in beta cells, implicating a wider role of ChREBP beyond regulation of hepatic enzymes \[[@CR40]\].

In summary, our data clearly demonstrate the critical role of dietary carbohydrates in the pathophysiology of HF-induced diabetes. LCM allows isolation of authentic pancreatic islet cells from their native tissue environment for genome-wide expression profiling. In islets, the diabetes-protective effect of a CHF diet correlates with reduced expression of genes for OXPHOS and antioxidants, suggesting a major contribution of ROS to diet-induced beta cell failure. Thus, our approach successfully identified candidate pathways and molecules that may play a role in the aetiology of type 2 diabetes.
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